

Original Article

Differential effects of short- and long-term zolpidem treatment on recombinant $\alpha 1\beta 2\gamma 2s$ subtype of GABA_A receptors *in vitro*

Josipa VLAINIĆ*, Maja Jazvinščak JEMBREK, Toni VLAINIĆ, Dubravka Švob ŠTRAC, Danka PERIČIĆ

Ruđer Bošković Institute, Division of Molecular Medicine, Laboratory of Molecular Neuropharmacology, POB 180, Zagreb, Croatia

Aim: Zolpidem is a non-benzodiazepine agonist at benzodiazepine binding site in GABA_A receptors, which is increasingly prescribed. Recent studies suggest that prolonged zolpidem treatment induces tolerance. The aim of this study was to explore the adaptive changes in GABA_A receptors following short and long-term exposure to zolpidem *in vitro*.

Methods: Human embryonic kidney (HEK) 293 cells stably expressing recombinant $\alpha 1\beta 2\gamma 2s$ GABA_A receptors were exposed to zolpidem (1 and 10 $\mu\text{mol/L}$) for short-term (2 h daily for 1, 2, or 3 consecutive days) or long-term (continuously for 48 h). Radioligand binding studies were used to determine the parameters of [³H]flunitrazepam binding sites.

Results: A single (2 h) or repeated (2 h daily for 2 or 3 d) short-term exposure to zolpidem affected neither the maximum number of [³H]flunitrazepam binding sites nor the affinity. In both control and short-term zolpidem treated groups, addition of GABA (1 nmol/L–1 mmol/L) enhanced [³H]flunitrazepam binding in a concentration-dependent manner. The maximum enhancement of [³H]flunitrazepam binding in short-term zolpidem treated group was not significantly different from that in the control group. In contrast, long-term exposure to zolpidem resulted in significantly increase in the maximum number of [³H]flunitrazepam binding sites without changing the affinity. Furthermore, long-term exposure to zolpidem significantly decreased the ability of GABA to stimulate [³H]flunitrazepam binding.

Conclusion: The results suggest that continuous, but not intermittent and short-term, zolpidem-exposure is able to induce adaptive changes in GABA_A receptors that could be related to the development of tolerance and dependence.

Keywords: GABA_A receptor; HEK 293 cells; Zolpidem; [³H]flunitrazepam binding

Acta Pharmacologica Sinica advance online publication, 27 Aug 2012; doi: 10.1038/aps.2012.89

Introduction

Gamma-aminobutyric acid type A (GABA_A) receptors are ligand gated ion channels activated physiologically by the main inhibitory neurotransmitter γ -aminobutyric acid (GABA). Functional GABA_A receptors are formed by five subunits derived from seven receptor subunit families ($\alpha 1$ –6, $\beta 1$ –3, $\gamma 1$ –3, δ , ϵ , θ , and π). Different subunit isoforms are expressed with regional specificity and in a cell-type specific manner^[1]. In the central nervous system, the most common receptor form is comprised of the $\alpha 1$, $\beta 2$, and $\gamma 2$ subunits, with a defined stoichiometry of $2\alpha:2\beta:1\gamma$ ^[2].

Imidazopyridine zolpidem is a non-benzodiazepine hypnotic that exerts its effects via the benzodiazepine binding site on GABA_A receptors. Zolpidem has a very high affinity for receptors containing the $\alpha 1$ subunit, has an intermedi-

ate affinity for receptors that contain $\alpha 2$ or $\alpha 3$, and does not interact with GABA_A receptors consisting of the $\alpha 5$ subunit^[3–6]. In addition to its sedative effects, zolpidem has considerable anticonvulsant activity^[7,8]. Moreover, recent studies provide a rationale for further investigations of its potential in the treatment of basal ganglia disorders^[9].

Benzodiazepines are widely used clinically to obtain one of the following major effects: decrease in sleep latency, reduction of anxiety, antiepileptic action or muscle relaxation. They are positive allosteric modulators of GABA_A receptors. Benzodiazepines bind to a binding pocket on the α/γ subunit interface. In general, benzodiazepines are safe and effective for short-term treatment. On the other hand, due to the development of tolerance and potential for dependence, the appropriateness of benzodiazepines for long-term use is controversial.

It has been supposed that drugs with a high selectivity for $\alpha 1$ containing receptors have fewer side effects compared to classical benzodiazepines. Although chemically different than benzodiazepines, zolpidem elicited many side effects simi-

* To whom correspondence should be addressed.

E-mail Josipa.Vlainic@irb.hr

Received 2012-03-23 Accepted 2012-06-06

lar to that of benzodiazepines. Vlainić and Peričić (2009)^[10] demonstrated development of anticonvulsant and sedative tolerance after repeated (10 days) zolpidem treatment in mice. Similar results were obtained in rats^[11]. Several studies have also suggested that zolpidem has a significant risk of abuse and dependence in humans^[12].

In their study, Vlainić and colleagues (2010)^[13] showed that a 2-day zolpidem (10 $\mu\text{mol/L}$) treatment enhances the number of recombinant $\alpha 1\beta 2\gamma 2\text{s}$ GABA_A receptors and produces functional uncoupling between GABA and benzodiazepine binding site. Moreover, the observed changes are not substantially different from those detected after prolonged exposure of these cells to high doses of the classical benzodiazepine, diazepam^[14]. Despite of many studies, the molecular mechanisms involved in the development of tolerance to the actions of benzodiazepines remain unknown^[15–17]. The aim of our study was to explore the molecular mechanisms induced by zolpidem treatment using radioligand binding assays.

Materials and methods

Cell culture

The human embryonic kidney (HEK) 293 cell line stably expressing the $\alpha 1\beta 2\gamma 2\text{s}$ subtype of GABA_A receptor was kindly donated by Dr David GRAHAM (Sanofi-Synthelabo Research, France). The cells were maintained in 75-cm² flasks at 37°C in humidified air with 5% CO₂ according to standard cell culture techniques. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum, 2 mmol/L L-glutamine, 100 units/mL penicillin and 100 $\mu\text{g/mL}$ streptomycin.

Drugs

Zolpidem [N,N,6-trimethyl-2-(4-methylphenyl)-imidazo(1,2-a)pyridine-3-acetamide] was a generous gift from Pliva (Zagreb, Croatia). [³H]flunitrazepam (specific activity 87 Ci/mmol) was purchased from Amersham Biosciences UK Ltd. Culture medium, antibiotics, fetal bovine serum and other chemicals were supplied from Invitrogen/Gibco (Grand Island, NY, USA).

Drug treatment

Cells were seeded onto new flasks and grown for 3 d prior to exposure to drugs. We had four different treatment regimens:

Continuous zolpidem treatment: on the initial day, the medium was replaced with a fresh medium containing zolpidem (final concentrations 1 and 10 $\mu\text{mol/L}$) for 48 h in the presence of 1 $\mu\text{mol/L}$ GABA.

Single dose of zolpidem (final concentrations 1 and 10 $\mu\text{mol/L}$): the medium containing zolpidem was replaced with fresh medium following a 2-h treatment period. The cells were grown in the presence of 1 $\mu\text{mol/L}$ GABA.

Zolpidem treatment for two consecutive days: the medium containing zolpidem (final concentrations 1 and 10 $\mu\text{mol/L}$) was replaced after a 2-h treatment with fresh medium. The same procedure (treatment/fresh medium) was repeated the next day. The cells were grown in the presence of 1 $\mu\text{mol/L}$

GABA.

Zolpidem treatment for three consecutive days: zolpidem (final concentrations 1 and 10 $\mu\text{mol/L}$) was added to the medium for a 2-h treatment period and then replaced with fresh medium. The same procedure was repeated for three consecutive days. The cells were grown in the presence of 1 $\mu\text{mol/L}$ GABA.

Zolpidem and GABA were dissolved in distilled water. The control cells were treated with corresponding vehicle in the presence of 1 $\mu\text{mol/L}$ GABA.

Radioligand binding studies

Preparation of the membranes

Membranes from stably transfected HEK 293 cells were prepared mainly as described by Peričić *et al* (2005)^[18]. Briefly, the cells were washed with phosphate-buffer saline (PBS), scraped from the flasks into ice-cold PBS, and centrifuged at 12000 $\times g$ for 12 min. The cell pellet was homogenized in 50 mmol/L Tris-citrate buffer at pH 7.4 by 10 strokes (up and down) at 1250 r/min using a teflon pestle and glass homogenizer. The cells were then centrifuged at 200000 $\times g$ for 20 min. The same procedure (re-suspension/ centrifugation) was repeated two more times. Finally, the pellet was re-suspended and stored in aliquots at -20°C. The cell membrane suspension was centrifuged once more on the day of the [³H]flunitrazepam binding assay at 200000 $\times g$ for 20 min.

[³H]flunitrazepam binding assay

Aliquots of the cell membrane preparation (~100 μg protein) were incubated in a 50 mmol/L Tris-citrate buffer supplemented with 150 mmol/L NaCl at 4°C for 90 min with the addition of varying concentrations of non-radioactive flunitrazepam (ten final concentrations in the range of 0.4–50 nmol/L) and a fixed concentration (1 nmol/L) of [³H]flunitrazepam. In stimulation studies, varying concentrations of GABA (1 nmol/L–1 mmol/L) were incubated with [³H]flunitrazepam (1 nmol/L). Non-specific binding was determined in the presence of 100 $\mu\text{mol/L}$ diazepam. Total assay volume of all binding studies was 0.5 mL. The radioactivity bound to the membranes was counted on a β -scintillation counter (Perkin Elmer, Wallace 1409DSA) after a rapid vacuum filtration on Whatman GF/C filters.

Using bovine serum albumin as a standard, the protein concentration was determined in 10 μL samples of each membrane suspension.

Data analysis

The analysis of binding data was performed using the GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, USA). The values dissociation constant (K_d) and maximum number of (³H)flunitrazepam binding sites (B_{max}) were obtained by nonlinear regression using the equation for a hyperbola (one binding site): $Y = B_{\text{max}} \times X / (K_d + X)$, where K_d is the concentration of ligand required to reach half-maximal binding and B_{max} is the maximum number of binding sites. The percentage of change in [³H]flunitrazepam binding pro-

duced by GABA was defined as (specific binding in the presence of GABA/specific binding in the absence of GABA)×100. The enhancement curves, analyzed using the sigmoidal equation, determined the values for half-maximum (EC_{50}) and the maximum enhancement (E_{max} , defined as absolute difference between the top and bottom plateau) of GABA-induced [3H] flunitrazepam binding.

Statistical evaluation was performed with one-way analysis of variance (ANOVA) followed by a *post-hoc* Newman-Keuls multiple comparison test. All data are expressed as the mean±SEM of at least three independent experiments performed in duplicate. *P*-values of less than 0.05 were considered significant.

Results

The effect of long-term zolpidem treatment on [3H]flunitrazepam binding to membranes from HEK 293 cells stably transfected with $\alpha 1\beta 2\gamma 2s$ subunits of GABA_A receptors

Long-term zolpidem treatment (1 and 10 $\mu\text{mol/L}$ for 48 h in the presence of 1 $\mu\text{mol/L}$ GABA) induced an up-regulation of benzodiazepine binding sites at recombinant $\alpha 1\beta 2\gamma 2s$ GABA_A receptors. As shown in Figure 1, zolpidem up-regulated the maximum number of benzodiazepine binding sites (B_{max}) by 35% and 104% (B_{max} values were as follows: control group, 2.95 ± 0.24 pmol/mg protein; 1 $\mu\text{mol/L}$ zolpidem treatment, 3.99 ± 0.51 pmol/mg protein; and 10 $\mu\text{mol/L}$ zolpidem treatment, 6.03 ± 0.18 pmol/mg protein). One-way ANOVA revealed significant differences between these groups [$F(2,15)=15.75$; $P<0.0003$], indicating that zolpidem treatment had a significant effect on the maximum number of benzodiazepine binding sites, whereas their affinity remained unchanged. K_d values were as follows: control group, 2.56 ± 0.32 nmol/L; 1 $\mu\text{mol/L}$ zolpidem treatment, 2.75 ± 0.44 nmol/L; and 10 $\mu\text{mol/L}$ zolpidem treatment, 2.62 ± 0.11 nmol/L.

The effect of short-term 1 $\mu\text{mol/L}$ zolpidem treatment on [3H]flunitrazepam binding to membranes from HEK 293 cells stably transfected with $\alpha 1\beta 2\gamma 2s$ subunits of GABA_A receptors

The cells were treated with 1 $\mu\text{mol/L}$ zolpidem once for 2 h, or for a 2-h period per day during two or three consecutive days in the presence of 1 $\mu\text{mol/L}$ GABA. As shown in Figure 2, intermittent short-term exposure of cells to 1 $\mu\text{mol/L}$ zolpidem did not induce adaptive changes in the maximum number of [3H]flunitrazepam binding sites at GABA_A receptors. The values for the maximum number of benzodiazepine binding sites were as follows: control group, 2.43 ± 0.34 pmol/mg protein; one-time, 2 h zolpidem treatment, 2.12 ± 0.26 pmol/mg protein; 2 h zolpidem treatment for two consecutive days, 2.11 ± 0.45 pmol/mg protein; and 2 h zolpidem treatment for three consecutive days, 1.92 ± 0.12 pmol/mg protein. One-way ANOVA did not reveal significant differences between these groups. In addition, the affinity of benzodiazepine binding sites was not affected with zolpidem treatment: control group, 2.87 ± 0.34 nmol/L; one-time, 2 h zolpidem treatment, 2.66 ± 0.26 nmol/L; 2 h zolpidem treatment for two consecutive days,




Figure 1. The effect of zolpidem treatment (1 and 10 $\mu\text{mol/L}$, 48 h) on the Scatchard plot (A), saturation isotherms (B), maximum number (C; B_{max}) and dissociation constant (D; K_d) of [3H]flunitrazepam binding sites on the membranes of HEK 293 cells stably transfected with $\alpha 1\beta 2\gamma 2s$ subunits of GABA_A receptors. Cell membranes were prepared and incubated with increasing concentrations of non-radioactive flunitrazepam (0.3–50 nmol/L) in the presence of 1 nmol/L [3H]flunitrazepam. B_{max} and K_d values were obtained by nonlinear regression using GraphPad Prism. Mean±SEM. $n=3$. ^b $P<0.05$ and ^c $P<0.01$ versus control group (ANOVA followed by the Newman-Keuls test).

2.66 ± 0.23 nmol/L; and 2 h zolpidem treatment for three consecutive days, 2.98 ± 0.21 nmol/L).




Figure 2. The effect of short-term zolpidem treatment (1 μmol/L for 2 h during one, two or three consecutive days) on the saturation isotherms (A), maximum number (B; B_{\max}) and dissociation constant (C; K_d) of [3 H]flunitrazepam binding sites on the membranes of HEK 293 cells stably transfected with $\alpha 1\beta 2\gamma 2s$ subunits of GABA_A receptors. Cell membranes were prepared and incubated with increasing concentrations of non-radioactive flunitrazepam (0.3–50 nmol/L) in the presence of 1 nmol/L [3 H]flunitrazepam. B_{\max} and K_d values were obtained by nonlinear regression using GraphPad Prism. The results are expressed as mean±SEM. $n=3$. Statistical analysis showed no significant changes among the groups (ANOVA followed by the Newman-Keuls test).

The effect of short-term 10 μmol/L zolpidem on [3 H]flunitrazepam binding to membranes from HEK 293 cells stably transfected with $\alpha 1\beta 2\gamma 2s$ subunits of GABA_A receptors

The cells were treated with 10 μmol/L zolpidem once for 2 h, or for a 2-h period per day during two or three consecutive days in the presence of 1 μmol/L GABA. As shown in Figure 3 and indicated by one-way ANOVA, there is no significant difference among these groups. The intermittent short-term zolpidem treatment (2 h once and during two or three consecutive days) did not affect [3 H]flunitrazepam binding parameters at recombinant $\alpha 1\beta 2\gamma 2s$ GABA_A receptors stably expressed in HEK 293 cells ($P<0.001$, ANOVA and Newman-




Figure 3. The effect of short-term zolpidem treatment (10 μmol/L for 2 h during one, two or three consecutive days) on the saturation isotherms (A), maximum number (B; B_{\max}) and dissociation constant (C; K_d) of [3 H]flunitrazepam binding sites on the membranes of HEK 293 cells stably transfected with $\alpha 1\beta 2\gamma 2s$ subunits of GABA_A receptors. Cell membranes were prepared and incubated with increasing concentrations of non-radioactive flunitrazepam (0.3–50 nmol/L) in the presence of 1 nmol/L [3 H]flunitrazepam. B_{\max} and K_d values were obtained by nonlinear regression using GraphPad Prism. The results are expressed as mean±SEM. $n=3$. Statistical analysis showed no significant changes among the groups (ANOVA followed by the Newman-Keuls test).

Keuls test). B_{\max} values for the control group were 2.45 ± 0.24 pmol/mg protein; one-time, 2 h zolpidem treatment, 1.77 ± 0.11 pmol/mg protein; 2 h zolpidem treatment for two consecutive days, 2.22 ± 0.07 pmol/mg protein; and 2 h zolpidem treatment for three consecutive days, 1.91 ± 0.20 pmol/mg protein. The affinity of benzodiazepine binding sites was not affected with zolpidem treatment. The dissociation constant for the control group was 3.75 ± 0.62 nmol/L; one-time, 2 h zolpidem treatment, 4.41 ± 0.36 nmol/L; 2 h zolpidem treatment for two consecutive days, 3.86 ± 0.22 nmol/L; and 2 h zolpidem treatment

for three consecutive days, 4.45 ± 0.69 nmol/L.

The effect of long-term zolpidem treatment (1 and 10 μ mol/L) on GABA-induced enhancement of [3 H]flunitrazepam binding to membranes of HEK 293 cells stably transfected with $\alpha 1\beta 2\gamma 2s$ subunits of GABA_A receptors

Long-term zolpidem treatment (1 and 10 μ mol/L) of HEK 293 cells enhanced basal [3 H]flunitrazepam binding to the same level as that observed in the maximum number of binding sites for benzodiazepines (B_{\max}). The addition of GABA (1 nmol/L–1 mmol/L) to membranes obtained from control and zolpidem pre-treated cells enhanced [3 H]flunitrazepam binding in a concentration-dependent manner. We present the data as the percentage of their own basal values and as the maximum enhancement (E_{\max}) of [3 H]flunitrazepam binding by GABA to better see the differences in the intensity of GABA-induced enhancement of [3 H]flunitrazepam binding (Figure 4). The maximum enhancement (E_{\max}) of [3 H]flunitrazepam binding produced by GABA in the control group was $79.3\% \pm 3.2\%$, indicating that the GABA binding site was functionally coupled to the benzodiazepine binding site. In the group treated with 1 μ mol/L zolpidem, the maximum enhancement of [3 H]flunitrazepam binding produced by GABA was significantly lower ($55.1\% \pm 7.9\%$). Moreover, in the group treated with 10 μ mol/L zolpidem, the maximum




Figure 4. The effect of zolpidem treatment (1 and 10 μ mol/L, 48 h) on GABA potentiation of [3 H]flunitrazepam binding to membranes of HEK 293 cells stably transfected with $\alpha 1\beta 2\gamma 2s$ subunits of GABA_A receptors. Data are expressed as percent of their own basal values (A) and as the maximum GABA-induced enhancements (B; E_{\max}) of [3 H]flunitrazepam binding. The points and bars are mean \pm SEM. $n=3-5$. $^{\circ}P < 0.01$ versus control group (ANOVA and Newman-Keuls test).

enhancement of [3 H]flunitrazepam binding was even lower ($44.2\% \pm 7.6\%$). These results indicate that allosteric interactions between GABA and benzodiazepine binding sites in zolpidem treated groups were uncoupled by 31% and 45%. One-way ANOVA indicated the significant difference [$F(2,15)=12.51$; $P < 0.0009$] between the analyzed groups. This difference was confirmed by Newman-Keuls test (control group versus group treated with 1 μ mol/L zolpidem $P < 0.05$; control group versus group treated with 10 μ mol/L zolpidem $P < 0.001$). As shown by analysis of enhancement curves, the concentrations of GABA that produced a half-maximum enhancement of [3 H]flunitrazepam binding (EC_{50}) were not different between the control group and the zolpidem-treated groups.

The effect of short-term 1 μ mol/L zolpidem treatment on GABA-induced enhancement of [3 H]flunitrazepam binding to membranes of HEK 293 cells stably transfected with $\alpha 1\beta 2\gamma 2s$ subunits of GABA_A receptors

The addition of GABA (1 nmol/L–1 mmol/L) to membranes obtained from control and zolpidem pre-treated cells enhanced [3 H]flunitrazepam binding in a concentration-dependent manner. The data are presented as a percentage of their own basal values and as the maximum enhancement (E_{\max}) of [3 H]flunitrazepam binding (Figure 5). In the control group,




Figure 5. The effect of short-term zolpidem (1 μ mol/L for 2 h during one, two or three consecutive days) treatment on [3 H]flunitrazepam binding to membranes from HEK 293 cells stably transfected with $\alpha 1\beta 2\gamma 2s$ subunits of GABA_A receptors. Data are expressed as percent of their own basal values (A) and as the maximum GABA-induced enhancements (B; E_{\max}) of [3 H]flunitrazepam binding. The points and bars are mean \pm SEM. $n=3$. Statistical analysis showed no significant change among the groups (ANOVA followed by the Newman-Keuls test).

the maximum enhancement of [3 H]flunitrazepam binding produced by GABA was $80.2\% \pm 3.6\%$, indicating that the GABA binding sites were functionally coupled to benzodiazepine binding sites. In the short-term zolpidem treated groups, the maximum enhancements were not significantly different from the one produced in the control group (E_{\max} values were: one-time, 2 h zolpidem treatment, $69.9\% \pm 3.8\%$; 2 h zolpidem treatment for two consecutive days, $67.1\% \pm 1.9\%$; and 2 h zolpidem treatment for three consecutive days, $71.4\% \pm 9.4\%$). The analysis of enhancement curves did not reveal differences in the concentrations of GABA that produced a half-maximum enhancement of [3 H]flunitrazepam binding (EC_{50}) in control and zolpidem treated groups.

The effect of short-term 10 μ mol/L zolpidem treatment on GABA-induced enhancement of [3 H]flunitrazepam binding to membranes of HEK 293 cells stably transfected with $\alpha 1\beta 2\gamma 2s$ subunits of GABA $_A$ receptors

The addition of GABA (1 nmol/L–1 mmol/L) to membranes obtained from control and zolpidem pre-treated cells enhanced [3 H]flunitrazepam binding in a concentration dependent manner. The data were introduced as a percentage of their own basal values and as a maximum enhancement (E_{\max}) of [3 H]flunitrazepam binding (Figure 6). The maximum enhancement of [3 H]flunitrazepam binding (E_{\max}) produced by GABA in




Figure 6. The effect of short-term zolpidem (10 μ mol/L for 2 h during one, two or three consecutive days) treatment on [3 H]flunitrazepam binding to membranes from HEK 293 cells stably transfected with $\alpha 1\beta 2\gamma 2s$ subunits of GABA $_A$ receptors. Data are expressed as percent of their own basal values (A) and as the maximum GABA-induced enhancements (B; E_{\max}) of [3 H]flunitrazepam binding. The points and bars are means \pm SEM. $n=3-5$. Statistical analysis showed no significant change among the groups (ANOVA followed by the Newman-Keuls test).

the control group was $82.3\% \pm 3.7\%$, indicating that the GABA binding sites were functionally coupled to the benzodiazepine binding sites. The maximum enhancements of [3 H]flunitrazepam binding in short-term zolpidem treated groups were not significantly different from the one produced in the control group (E_{\max} values were: one-time, 2 h zolpidem treatment, $67.4\% \pm 7.8\%$; 2 h zolpidem treatment for two consecutive days, $67.6\% \pm 2.2\%$; and 2 h zolpidem treatment for three consecutive days, $72.55\% \pm 4.1\%$). The analysis of enhancement curves did not reveal differences in the concentrations of GABA that produced a half-maximum enhancement of [3 H]flunitrazepam binding (EC_{50}) in control and zolpidem treated groups.

Discussion

Recent studies have provided evidence that benzodiazepines share the pharmacological profile of addictive drugs through cell-type specific expression of $\alpha 1$ -containing GABA $_A$ receptors^[13, 14, 19]. Non-benzodiazepine zolpidem acts selectively at $\alpha 1$ subunit-containing GABA $_A$ receptors and is considered to be devoid of addiction liability. To test whether zolpidem induces similar molecular changes as those reported to be linked to the development of tolerance, we conducted several experiments. The present results demonstrate that a single (2 h) or repeated (2 h per day for 2 or 3 d) exposure of stably transfected HEK 293 cells expressing recombinant $\alpha 1\beta 2\gamma 2s$ GABA $_A$ receptors to hypnotic zolpidem did not affect the maximum number of [3 H]flunitrazepam binding sites and their affinity. Stimulation studies revealed that the ability of GABA to potentiate [3 H]flunitrazepam binding in the control and short-term treated groups was not affected. In contrast, long-term (48 h) exposure of these cells to 1 or 10 μ mol/L zolpidem enhanced the maximum number of benzodiazepine binding sites without changing their affinity. Long-term zolpidem occupation (48 h) of benzodiazepine binding sites at GABA $_A$ receptors produced a partial allosteric uncoupling of GABA and benzodiazepine binding sites, as evidenced by decreased ability of GABA to stimulate [3 H]flunitrazepam binding.

It has been shown that a single intra-peritoneal injection of benzodiazepines is sufficient to induce synaptic plasticity in mice. It is postulated that observed early adaptive changes are not sufficient to explain long-term development of addiction. Instead, they represent an imperative initial step that triggers synaptic changes in addiction if the use of drug becomes chronic. Furthermore, it has been shown that benzodiazepine-induced changes in synaptic plasticity depend on $\alpha 1$ -containing GABA $_A$ receptors because the observed changes are abolished in $\alpha 1$ -H101R knock-in mice^[19]. In our model, a single dose of zolpidem and short-term intermittent zolpidem treatment did not induce molecular changes at GABA $_A$ receptors regarding receptor number and GABA potentiation. This suggests that zolpidem might have a lower propensity for inducing molecular changes at GABA $_A$ receptors, possibly associated with the development of tolerance if used in a strict daily regime. On the other hand, as shown recently, long-term continuous occupation of GABA $_A$ receptors with zolpidem can induce adaptive changes at GABA $_A$ receptors^[13]. It should be

mentioned that these changes are not substantially different from those obtained after prolonged exposure of these cells to high doses of classical benzodiazepine-diazepam^[14, 20]. Moreover, Vlainić *et al* (2010)^[13] assumed that prolonged zolpidem treatment induces an increase of cell-surface GABA_A receptors that are functionally active. Several potential mechanisms could underlie the up-regulation of GABA_A receptor number: an increased synthesis, a decreased degradation of receptor proteins or an enhanced rate of receptor incorporation into membranes. The same authors also showed an increased level of $\alpha 1$ subunit mRNA and $\gamma 2$ subunit proteins suggesting at least a partial role of transcriptional mechanisms in zolpidem-induced enhancement of GABA_A receptors. Although mRNA changes do not necessarily reflect changes in protein expression^[21, 22], Uusi-Oukari *et al* (2000)^[1] showed that there is tight control between the expression of $\alpha 1$ subunit mRNA and polypeptide. Moreover, it has been demonstrated that benzodiazepines regulate $\alpha 1$ ^[23] and $\gamma 2$ ^[24] subunit mRNA at the level of transcription. A general trophic effect of zolpidem treatment on the growth of HEK 293 cells could presumably be excluded because total cellular proteins did not vary between the control and zolpidem-pre-treated group (data not shown).

Furthermore, 2-d zolpidem treatment produced functional uncoupling between the GABA and benzodiazepine binding sites, as demonstrated by the study of Primus *et al* (1996)^[25]. The functional consequences of zolpidem-induced augmentation of GABA_A receptor number observed in the study along with the reduced functional coupling were not determined. The exact molecular mechanism(s) leading to functional uncoupling between GABA and benzodiazepine binding sites remain unknown. Although uncoupling of the benzodiazepine and GABA binding sites could be produced by drugs inhibiting protein kinase A, it is supposed that direct phosphorylation of GABA_A receptors is not involved in coupling/uncoupling processes^[26]. The same authors proposed that prolonged benzodiazepine treatment induces internalization of surface GABA_A receptors into intracellular vesicles, where the potentiation by GABA is impaired but the normal benzodiazepine binding can occur. However, several studies^[20, 25] have failed to support the internalization model of GABA_A receptors. The observed reduction in functional coupling between GABA and benzodiazepine binding sites could represent a conformational change at the receptor binding sites. It has been suggested that residues in and surrounding benzodiazepine binding site are aligned with the residues that form the GABA binding site^[27]. Morlock and Czajkowski (2011)^[28] speculated that the positioning of the drug at the benzodiazepine binding site and/or the positioning of nearby residues induces different downstream allosteric rearrangements. Thus, allosteric uncoupling between GABA and benzodiazepine binding sites leads to a reduced potency of benzodiazepines. One cannot conclude that zolpidem-mediated activity in animals and humans will be reduced because prolonged zolpidem treatment produced an increase in GABA_A receptor number. However, long-term administration of non-selective full positive allosteric modulator of GABA action at GABA_A receptors

leads to alterations in receptor expression and/or function, resulting in the development of tolerance and dependence. Many authors working either on animals^[29], neuronal cultures^[30-32] or recombinant receptors^[13, 14, 20, 25, 26, 33, 34] have found reduced allosteric linkage between GABA and benzodiazepine binding sites as a result of prolonged benzodiazepine action. Moreover, animals and humans treated for prolonged period of time with drugs acting as full positive modulators of GABA action at GABA_A receptors developed tolerance characterized by a decreased ability of the drug to produce its pharmacological effect. Although it appears that allosteric uncoupling could explain the development of tolerance, the molecular mechanisms are rather more complex^[15, 17].

In conclusion, it should be mentioned that zolpidem, which is highly selective for $\alpha 1$ subunit of GABA_A receptors and is claimed to carry a low risk for addiction during long-term treatment, induces adaptive changes that are rather similar to those produced by long-term benzodiazepine treatment. Previous studies on mice^[10] and rats^[11] suggested that, upon repeated treatment, zolpidem produced tolerance to its anti-convulsive and sedative effects. Therefore, zolpidem has a higher abuse potential than previously suggested^[12]. Since 2002, the World Health Organization has considered the frequency of zolpidem abuse and dependence to be similar to that of benzodiazepines.

Our results on intermittent short-term exposure suggest that, if used in a strong daily regime, zolpidem does not produce changes at recombinant GABA_A receptors stably expressed in HEK 293 cells. This could presumably be associated with the development of tolerance, as it is with the continuous treatment^[13, 35]. The observed changes are not substantially different from those obtained after prolonged exposure of cells to high doses of classical benzodiazepines^[14].

Acknowledgements

The study was supported by the Croatian Ministry of Science, Education and Sports (Project: Stress, GABA_A receptors and mechanisms of action of neuro-psychoactive drugs). The skillful technical assistance of Mrs Zlatica TONŠETIĆ is gratefully acknowledged.

Author contribution

Josipa VLAINIĆ and Danka PERIČIĆ conceived and designed the experiments. Maja Jazvinščak JEMBREK and Josipa VLAINIĆ performed the experiments. Toni VLAINIĆ analyzed the data. Josipa VLAINIĆ and Toni VLAINIĆ wrote the paper. Dubravka Švob ŠTRAC helped with linguistic formulation of the text.

References

- 1 Uusi-Oukari M, Heikkilä J, Sinkkonen ST, Mäkelä R, Hauer B, Homanics GE, *et al*. Long-range interactions in neuronal gene expression: evidence from gene targeting in the GABA_A receptor $\beta 2$ - $\alpha 6$ - $\alpha 1$ - $\gamma 2$ subunit gene cluster. *Mol Cell Neurosci* 2000; 16: 34–41.
- 2 Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid (A) receptors: classification on

- the basis of subunit composition, pharmacology, and function. *Pharmacol Rev* 2008; 60: 243–60.
- 3 Arbilla S, Depoortere H, George P, Langer SZ. Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats. *Naunyn Schmiedeberg's Arch Pharmacol* 1985; 330: 248–51.
 - 4 Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, et al. Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. *J Pharmacol Exp Ther* 1986; 237: 649–58.
 - 5 Sanna E, Busonero F, Talani G, Carta M, Massa F, Peis M, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. *Eur J Pharmacol* 2002; 451: 103–10.
 - 6 Ci SQ, Ren TR, Ma CX, Su ZG. Modeling of $\alpha 1/\gamma 2$ ($k=1, 2, 3$ and 5) interface of GABA_A receptor and docking studies with zolpidem: implications for selectivity. *J Mol Graph Model* 2007; 26: 537–45.
 - 7 Perićić D, Vlainić J, Švob Štrac D. Sedative and anticonvulsant effects of zolpidem in adult and aged mice. *J Neural Transm* 2008; 115: 795–802.
 - 8 Vlainić J, Perićić D. Zolpidem is a potent anticonvulsant in adult and aged mice. *Brain Res* 2010; 1310: 181–8.
 - 9 Zhang LL, Chen L, Xue Y, Yung WH. Modulation of synaptic GABA_A receptor function by zolpidem in substantia nigra pars reticulata. *Acta Pharmacol Sin* 2008; 29: 161–8.
 - 10 Vlainić J, Perićić D. Effect of acute and repeated zolpidem treatment on pentylenetetrazole-induced seizure threshold and on locomotor activity: comparison with diazepam. *Neuropharmacol* 2009; 56: 1124–30.
 - 11 Auta J, Impagnatiello F, Kadriu B, Guidotti A, Costa E. Imidazenil: a low efficacy agonist at $\alpha 1$ - but high efficacy at $\alpha 5$ -GABA_A receptors fail to show anticonvulsant cross tolerance to diazepam or zolpidem. *Neuropharmacol* 2008; 55: 148–53.
 - 12 Victorri-Vigneau C, Dailly E, Veyrac G, Jolliet P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. *Br J Clin Pharmacol* 2007; 64: 198–209.
 - 13 Vlainić J, Jazvinščak Jembrek M, Švob Štrac D, Perićić D. The effects of zolpidem treatment and withdrawal on the *in vitro* expression of recombinant $\alpha 1\beta 2\gamma 2$ s GABA_A receptors expressed in HEK 293 cells. *Naunyn Schmiedeberg's Arch Pharmacol* 2010; 382: 201–12.
 - 14 Švob Štrac D, Vlainić J, Jazvinščak Jembrek M, Perićić D. Differential effects of diazepam treatment and withdrawal on recombinant GABA_A receptor expression and functional coupling. *Brain Res* 2008; 1246: 29–40.
 - 15 Bateson AN. Basic pharmacological mechanisms involved in benzodiazepine tolerance and withdrawal. *Curr Pharm Des* 2002; 8: 5–21.
 - 16 Uusi-Oukari M, Korpi ER. Regulation of GABA_A receptor subunit expression by pharmacological agents. *Pharmacol Rev* 2010; 62: 97–135.
 - 17 Tan KR, Rudolph U, Lüscher C. Hooked on benzodiazepines: GABA_A receptor subtypes and addiction. *Trends Neurosci* 2011; 34: 188–97.
 - 18 Perićić D, Jazvinščak Jembrek M, Švob Štrac D, Lazić J, Špoljarić IR. Enhancement of benzodiazepine binding sites following chronic treatment with flumazenil. *Eur J Pharmacol* 2005; 507: 7–13.
 - 19 Tan KR, Brown M, Labouèbe G, Yvon C, Creton C, Fritschy JM, et al. Neural bases for addictive properties of benzodiazepines. *Nature* 2010; 463: 769–74.
 - 20 Perićić D, Švob Štrac D, Jazvinščak Jembrek M, Vlainić J. Allosteric uncoupling and up-regulation of benzodiazepine and GABA recognition sites following chronic diazepam treatment of HEK 293 cells stably transfected with $\alpha 1\beta 2\gamma 2$ s subunits of GABA(A) receptors. *Naunyn Schmiedeberg's Arch Pharmacol* 2007; 375: 177–87.
 - 21 Impagnatiello F, Pesold C, Longone P, Caruncho H, Fritschy JM, Costa E, et al. Modifications of γ -aminobutyric acid A receptor subunit expression in rat neocortex during tolerance to diazepam. *Mol Pharmacol* 1996; 49: 822–31.
 - 22 Pesold C, Caruncho HJ, Impagnatiello F, Berg MJ, Fritschy JM, Guidotti A, et al. Tolerance to diazepam and changes at GABA_A receptor subunit expression in rat neocortical areas. *Neuroscience* 1997; 79: 477–87.
 - 23 Kang I, Lindquist DG, Kinane B, Ercolani L, Pritchard GA, Miller LG. Isolation and characterization of the promoter of the human GABA_A receptor $\alpha 1$ subunit gene. *J Neurochem* 1994; 62: 1643–6.
 - 24 Holt RA, Bateson AN, Martin IL. Chronic zolpidem treatment alters GABA(A) receptor mRNA levels in the rat cortex. *Eur J Pharmacol* 1997; 329: 129–32.
 - 25 Primus RJ, Yu J, Xu J, Hartnett C, Meyyappan M, Kostas C, et al. Allosteric uncoupling after chronic benzodiazepine exposure of recombinant γ -aminobutyric acid A receptors expressed in Sf9 cells: ligand efficacy and subtype selectivity. *J Pharmacol Exp Ther* 1996; 276: 882–90.
 - 26 Ali NJ, Olsen RW. Chronic benzodiazepine treatment of cells expressing recombinant GABA(A) receptors uncouples allosteric binding: studies on possible mechanisms. *J Neurochem* 2001; 79: 1100–8.
 - 27 Williams DB, Akabas MH. Evidence for distinct conformations of the two $\alpha 1$ subunits in diazepam-bound GABA(A) receptors. *Neuropharmacol* 2001; 41: 539–45.
 - 28 Morlock EV, Czajkowski C. Different residues in the GABA_A receptor benzodiazepine binding pocket mediate benzodiazepine efficacy and binding. *Mol Pharmacol* 2011; 80: 14–22.
 - 29 Gallager DW, Lakoski JM, Gonsalves SF, Rauch SL. Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity. *Nature* 1984; 308: 74–7.
 - 30 Roca DJ, Schiller GD, Friedman L, Rozenberg I, Gibbs TT, Farb DH. γ -Aminobutyric acid A receptor regulation in culture: altered allosteric interactions following prolonged exposure to benzodiazepines, barbiturates, and methylxanthines. *Mol Pharmacol* 1990; 37: 710–9.
 - 31 Hu XJ, Ticku MK. Chronic benzodiazepine agonist treatment reduces functional uncoupling of the γ -aminobutyric acid-benzodiazepine receptor ionophore complex in cortical neurons. *Mol Pharmacol* 1994; 45: 618–25.
 - 32 Friedman LK, Gibbs TT, Farb DH. Gamma-aminobutyric acidA receptor regulation: heterologous uncoupling of modulatory site interactions induced by chronic steroid, barbiturate, benzodiazepine, or GABA treatment in culture. *Brain Res* 1996; 707: 100–9.
 - 33 Klein RL, Whiting PJ, Harris RA. Benzodiazepine treatment causes uncoupling of recombinant GABA_A receptors expressed in stably transfected cells. *J Neurochem* 1994; 63: 2349–52.
 - 34 Klein RL, Mascia MP, Harkness PC, Hadingham KL, Whiting PJ, Harris RA. Regulation of allosteric coupling and function of stably expressed γ -aminobutyric acid (GABA)_A receptors by chronic treatment with GABA_A and benzodiazepine agonists. *J Pharmacol Exp Ther* 1995; 274: 1484–92.
 - 35 Vlainić J, Štrac DŠ, Jembrek MJ, Vlainić T, Perićić D. The effects of zolpidem treatment on GABA(A) receptors in cultured cerebellar granule cells: changes in functional coupling. *Life Sci* 2012; 90: 889–94.